ABHD17A

Across TCGA pan-cancer cohorts, ABHD17A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ABHD17A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ABHD17A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ABHD17A is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where ABHD17A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABHD17A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	III,IV	−0.491	<.001	9	view →
LUAD	Male	All	−0.300	<.001	9	view →
HNSC	All	All	−0.294	<.001	8	view →
CCRCC	Male	III,IV	+0.389	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ABHD17A–LSCC

Open the LSCC breakdown →